Constulose (Lactulose) - Summary

CONSTULOSE SUMMARY

LACTULOSE SOLUTION, USP 10 g/15 mL

Lactulose is a synthetic disaccharide in solution form for oral administration. Each 15 mL of lactulose solution contains: 10 g lactulose (and less than 1.6 g galactose, less than 1.2 g lactose, and 0.1 g or less of fructose). Lactulose solution contains potassium sorbate as an inactive ingredient. Lactulose is a colonic acidifier which promotes laxation.

Constulose (lactulose) is indicated for the following:

For the treatment of constipation. In patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur.

See all Constulose indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Constulose (Lactulose)

Digestive Disorders Pictures Slideshow: Constipation Myths and Facts
Source: MedicineNet Constipation Specialty [2013.05.09]
Title: Digestive Disorders Pictures Slideshow: Constipation Myths and Facts
Category: Slideshows
Created: 5/9/2013 12:00:00 AM
Last Editorial Review: 5/9/2013 12:00:00 AM

Health Tip: Help Prevent Constipation
Source: MedicineNet Constipation Specialty [2013.02.22]
Title: Health Tip: Help Prevent Constipation
Category: Health News
Created: 2/22/2013 8:35:00 AM
Last Editorial Review: 2/22/2013 12:00:00 AM

Constipation Treatments Not Equally Effective: Review
Source: MedicineNet Constipation Specialty [2013.01.29]
Title: Constipation Treatments Not Equally Effective: Review
Category: Health News
Created: 1/28/2013 12:35:00 PM
Last Editorial Review: 1/29/2013 12:00:00 AM

Linzess (Linaclotide) For IBS With Constipation Or Chronic Idiopathic Constipation Now Available, USA
Source: Irritable-Bowel Syndrome News From Medical News Today [2012.12.27]
Linzess (linaclotide), a medication for irritable bowel syndrome (IBS) with constipation or chronic idiopathic constipation is now available in American pharmacies, Ironwood Pharmaceuticals Inc. and Forest Laboratories Inc announced...

Linaclotide Given Positive CHMP Opinion For Irritable Bowel Syndrome With Constipation
Source: Irritable-Bowel Syndrome News From Medical News Today [2012.10.01]
Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) have announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the marketing approval for Constella® (linaclotide 290 micrograms), for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults...

more news >>

Published Studies Related to Constulose (Lactulose)

A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. [2011.08]
BACKGROUND: Minimal hepatic encephalopathy (MHE) impairs daily functioning and health-related quality of life (HRQoL). The modalities of treatment of MHE have not been adequately studied. AIMS: To compare lactulose, probiotics, and L-ornithine L-aspartate (LOLA) in treatment of MHE and effect on HRQoL by Sickness Impact Profile questionnaire... CONCLUSION: Lactulose, probiotics, and LOLA significantly improve MHE and HRQoL in patients with chronic liver disease.

Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. [2011.06]
BACKGROUND AND AIMS: Acute variceal bleed (AVB) is an important precipitating factor for development of hepatic encephalopathy (HE). However, there is paucity of data on the role of lactulose for prevention of HE after AVB. We evaluated the role of lactulose for prophylaxis of HE after AVB... CONCLUSIONS: Lactulose is effective in prevention of HE in patients with cirrhosis and acute variceal bleed. (c) 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Can partially hydrolyzed guar gum be an alternative to lactulose in treatment of childhood constipation? [2010.12]
BACKGROUND/AIMS: In the present study, we aimed to investigate if partially hydrolyzed guar gum (PHGG) can be used safely as a fiber source for treatment of constipation in children and to compare its success with the most commonly used osmotic laxative, lactulose... CONCLUSIONS: Treatment with partially hydrolyzed guar gum is as effective as lactulose treatment in relieving stool withholding and constipation-associated abdominal pain, and its use improves stool consistency. Lactulose seemed to have more side effects, including flatulence and sensation of bad taste.

Gastric emptying and orocaecal transit time of meals containing lactulose or inulin in men. [2010.08]
The H(2) breath test is ideal for orocaecal transit time (OCTT) measurement, as it is non-invasive and inexpensive. Indigestible substrates added to a test meal are metabolised by the colonic bacteria, resulting in the production of H(2) which is detected in end-exhalation breath...

The effects of lactulose supplementation to enteral feedings in premature infants: a pilot study. [2010.02]
OBJECTIVE: To assess the safety and prebiotic effects of lactulose in preterm infants... CONCLUSIONS: This pilot study supports the safety of supplementing preterm infants' feeds with low doses of lactulose. It also demonstrated trends that may suggest positive prebiotic effects. Copyright 2010 Mosby, Inc. All rights reserved.

more studies >>

Clinical Trials Related to Constulose (Lactulose)

Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis [Recruiting]
To assess the effects of lactulose for the prevention of first episode of altered sensorium (hepatic encephalopathy, primary prophylaxis) in patients with cirrhosis.

Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial [Recruiting]
The study will be double blind with respect to rifaximin, and randomization will be performed using tables of computer-generated random numbers. All subjects will be followed up till the recovery of HE (primary end point) or 10 days whichever is earlier. In the Lactulose group (group A) patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day along with placebo . In the lactulose plus rifaximin group (group B) patients will receive cap rifaximin 400mg three times a day along with lactulose. Primary endpoints will be recovery of overt HE patients who will not recover from HE after 10 days will be continued on the same treatment. Total duration of the study is 1 year.

Pilot Study of the Effect of Lactulose on Post Caesarean Section Constipation [Not yet recruiting]
Constipation following elective Caesarean sections (CS) is a common problem experienced by up to 50% of patients (1). The causes for this are multifactorial and include manipulation of the bowel during surgery, immobilisation and opiate based anaesthetic and analgesic techniques. To try to alleviate the problem of postoperative constipation, some anaesthetists prescribe postoperative lactulose in addition to postoperative analgesia, although no data exists that shows whether this has any beneficial effect on postoperative constipation.

1. Short term morbidity associated with Caesarean delivery. Hillan EM. Birth. 19 (4): 190-4).

Efficacy of Combined Oral L-Ornithine-L-Aspartate and Lactulose in Patients With Hepatic Encephalopathy [Recruiting]

A Preference Study Comparing Kristalose® and Liquid Lactulose [Not yet recruiting]
This study will evaluate whether patients have an overall preference for Kristalose® or liquid lactulose based on taste, consistency, and portability.

more trials >>